Dr. Le of the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center has announced that a phase II trial has shown that serial administration of two cancer vaccines has produced a positive improvement in the survival times for sufferers of metastatic pancreatic cancer.
The trail saw patients receive the GVAX Pancreas vaccine followed by CRS-207. The interim results show that overall survival was increased to 6 months, compared to the 4 months with GVAX alone.
The trial, sponsored by Aduro BioTech, actually met it’s criteria for efficacy early and as such patients in the single-vaccine trial are receiving both.
GVAX Pancreas is a therapeutic vaccine composed of cancer cells that have been genetically-modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) to stimulate the immune system. The cells have been irradiated to prevent further cell division.
CRS-207 is an attenuated form of Listeria monocytogenes that has been genetically modified to reduce its capacity to cause disease, while maintaining its ability to stimulate potent innate and adaptive immunity.
See the ClinicalTrials.gov entry here.